ATC Group: N05AD08 Droperidol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N05AD08 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N05 Psycholeptics
3 N05A Antipsychotics
4 N05AD Butyrophenone derivatives
5 N05AD08 Droperidol

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
PAREN - Parenteral 2.5 mg

Active ingredients in N05AD08

Active Ingredient Description
Droperidol

Droperidol is a butyrophenone neuroleptic. Its pharmacologic profile is characterised mainly by dopamine-blocking and weak α1-adrenolytic effects. Droperidol is devoid of anticholinergic and antihistaminic activity.

Related product monographs

Title Information Source Document Type  
XOMOLIX Solution for injection Medicines & Healthcare Products Regulatory Agency (GB) MPI, EU: SmPC

Medicines in this ATC group

Austria (AT)

Brazil (BR)

France (FR)

Ireland (IE)

Japan (JP)

New Zealand (NZ)

South Africa (ZA)

Spain (ES)

United Kingdom (UK)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.